All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
On 25th July 2017, in an article published in Blood Advances, Prajwal Boddu and colleagues from The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, reported results from their retrospective study which aimed to further refine the prognosis of Secondary Acute Myeloid Leukemia (sAML) arising from Antecedent Hematological Disorder (AHD). In particular, they reported on the outcomes of patients who developed AML as a result of a previously treated secondary AHD (ts-AML).
In total, 2,912 newly diagnosed AML patients who were treated at the MDACC between January 2000–December 2015 were retrospectively analyzed in this study. Of these 2,912 patients, 254 (9%) were designated ts-AML and 2,658 patients were designated as a non-ts-AML population.
Patients were further stratified into two study groups including younger patients who were < 60 years (n = 1,160 [ts-AML, n = 51, median age = 52 years]) and older patients who were > 60 years (n = 1,752 [ts-AML, n = 202, median age = 71 years]).
In summary, “poor outcomes in ts-AML are a combined translation of low response rates, high early mortality, and higher risk of early disease relapse”. Additionally, the outcomes of ts-AML patients were “uniformly dismal regardless of age”.
The authors concluded by proposing that “s-AML should be narrowed to define ts-AML, a category of AML typically less responsive to currently applied treatment approaches”.
Secondary acute myeloid leukemia (s-AML) includes therapy-related AML and AML evolving from antecedent hematological disorder (AHD). s-AML arising after treating AHD likely represents a prognostically distinct, high-risk disease category. In this study, treated s-AML (ts-AML) was defined by: (1) prior diagnosis of myelodysplasia, myeloproliferative neoplasm, or aplastic anemia and (2) at least 1 therapy for that diagnosis. ts-AML was categorized by age (< or ≥60 years), and each cohort assessed for response rates and overall survival (OS) on various treatment regimens. Survival outcomes were compared against other high-risk prognostic subsets. Results showed that complete response and 8-week mortality rates were 32% and 27% in the younger, and 24% and 19% in the older age groups, respectively. There was a significant OS difference within s-AML based on prior treatment of AHD (ie, ts-AML vs s-AML with untreated AHD, 4.2 vs 9.2 months; P < .001). Survival in ts-AML was poor across both cohorts (younger and older, 5 and 4.7 months, respectively). In younger AML, survival was significantly inferior in ts-AML when compared with deletion 5/7, TP53, 3q abnormality, and therapy-related AML groups (median, 5 vs 7.9, 7.8, 7.9, and 11.2 months, respectively; P < .01). Additional adverse karyotype within ts-AML was associated with even worse outcomes (OS range, 1.6-2.8 months). ts-AML represents a very high-risk category, even in younger AML patients. s-AML should be further classified to describe ts-AML, an entity less responsive to currently applied treatment approaches. Future AML trial designs should accommodate ts-AML as a distinct subgroup.
References
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?